Identification of the risks in CAR T-cell therapy clinical trials in China: a Delphi study
Aims: Within the past few years, there has been tremendous growth in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. Unlike those of many small-molecule pharmaceuticals, CAR T-cell therapy clinical trials are fraught with risks due to the use of live cell products. The aim of th...
Main Authors: | Weijia Wu, Yan Huo, Xueying Ding, Yuhong Zhou, Shengying Gu, Yuan Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-10-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920966574 |
Similar Items
-
Clinical trials of CAR-T cells in China
by: Bingshan Liu, et al.
Published: (2017-10-01) -
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
by: Nikola A. Ivica, et al.
Published: (2021-08-01) -
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020)
by: Ivica, Nikola A., et al.
Published: (2021) -
Seatbelts in CAR therapy: How Safe Are CARS?
by: Kentaro Minagawa, et al.
Published: (2015-05-01) -
The Application of Nanobody in CAR-T Therapy
by: Chaolemeng Bao, et al.
Published: (2021-02-01)